Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metastatic Breast Cancer - Pipeline Review, H2 2016, provides an overview of the Metastatic Breast Cancer (Oncology) pipeline landscape.
Metastatic breast cancer (also called Stage IV or Advanced) is a stage of breast cancer in which cancer cells break away from the tumor in the breast, spread to other parts of the body and keep growing. Symptoms of metastatic breast cancer includes severe, progressive pain, and, less commonly, pathological fracture, erythema over the affected bone, swelling, jaundice, elevated liver enzymes, abdominal pain, loss of appetite, nausea, and vomiting. Other symptoms include fatigue, malaise and weight loss. Treatment includes hormone therapy, chemotherapy, radiation therapy and surgery.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Metastatic Breast Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Metastatic Breast Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Metastatic Breast Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Metastatic Breast Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 33, 81, 52, 2, 52, 7 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 7, 7 and 1 molecules, respectively.Metastatic Breast Cancer.
Metastatic Breast Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Metastatic Breast Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Metastatic Breast Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Metastatic Breast Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Metastatic Breast Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Metastatic Breast Cancer (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Metastatic Breast Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Metastatic Breast Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
3SBio Inc
AB Science SA
AbbVie Inc
Acceleron Pharma Inc
Acetylon Pharmaceuticals Inc
Adgero Biopharmaceuticals Inc
Advaxis Inc
Advenchen Laboratories LLC
Alteogen Inc
Amarna Therapeutics BV
Ambrx Inc
Amgen Inc
Aphios Corp
Arvinas Inc
Aslan Pharmaceuticals Pte Ltd
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Bayer AG
Beta Pharma Inc
Biocon Ltd
Bionovis SA
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Cantex Pharmaceuticals Inc
Cascadian Therapeutics Inc
CASI Pharmaceuticals Inc
Celgene Corp
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Celltrion Inc
Clovis Oncology Inc
Corcept Therapeutics Inc
CSPC Pharmaceutical Group Limited
Curadis GmbH
Curaxys SL
Daiichi Sankyo Company Ltd
Deciphera Pharmaceuticals LLC
DexTech Medical AB
Dompe Farmaceutici SpA
Dr. Reddy's Laboratories Ltd
EirGenix Inc
Eisai Co Ltd
Eli Lilly and Company
Ensol Biosciences Inc
EOS Biosciences Inc
Epigen Biosciences Inc
Etubics Corp
F. Hoffmann-La Roche Ltd
FibroGen Inc
Gene Techno Science Co Ltd
Genelux Corp
Genentech Inc
Genor BioPharma Co Ltd
Gilead Sciences Inc
Glycotope GmbH
GP Pharm SA
GTx Inc
Halozyme Therapeutics Inc
Hanmi Pharmaceuticals Co Ltd
Hetero Drugs Ltd
Humorigin Biotechnology Corp
Immune Design Corp
Immunomedics Inc
Immunophotonics Inc
Immupharma Plc
Incyte Corp
Intas Pharmaceuticals Ltd
Ionis Pharmaceuticals Inc
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Kadmon Corp LLC
Kancera AB
Karyopharm Therapeutics Inc
Laboratoires Pierre Fabre SA
Mabion SA
MacroGenics Inc
MandalMed Inc
Meabco A/S
MedImmune LLC
Medivation Inc
Merck & Co Inc
Merck KGaA
Merrimack Pharmaceuticals Inc
Merus NV
MetaStat Inc
Millennium Pharmaceuticals Inc
Morphotek Inc
Mycenax Biotech Inc
NantKwest Inc
Natco Pharma Ltd
Nektar Therapeutics
Neonc Technologies Inc
NewLink Genetics Corp
Nippon Kayaku Co Ltd
Northwest Biotherapeutics Inc
Novartis AG
Oasmia Pharmaceutical AB
OBI Pharma Inc
Oncobiologics Inc
Oncolytics Biotech Inc
OncoMed Pharmaceuticals Inc
Ono Pharmaceutical Co Ltd
Panacea Pharmaceuticals Inc
Paras Biopharmaceuticals Finland Oy
Pfizer Inc
Pharma Mar SA
PIQUR Therapeutics AG
Plexxikon Inc
Polaris Pharmaceuticals Inc
Polyphor Ltd
Prescient Therapeutics Ltd
Prima BioMed Ltd
Puma Biotechnology Inc
Radius Health Inc
Richter Gedeon Nyrt
Samyang Holdings Corp
Sanofi
Seattle Genetics Inc
Shanghai Henlius Biotech Co Ltd
Sorrento Therapeutics Inc
Starpharma Holdings Ltd
Sun Pharma Advanced Research Company Ltd
SynCore Biotechnology Co Ltd
Syndax Pharmaceuticals Inc
Synthon Holdings BV
Taiho Pharmaceutical Co Ltd
Takeda Pharmaceutical Company Ltd
Tocagen Inc
Transgene Biotek Ltd
Tyme Technologies Inc
Vaxil Bio Therapeutics Ltd
Vertex Pharmaceuticals Inc
VioQuest Pharmaceuticals Inc
Vyriad Inc
Wilex AG
WntResearch AB
ZIOPHARM Oncology Inc
Zymeworks Inc
'
Table of Contents
Table of Contents 2
Introduction 9
Metastatic Breast Cancer Overview 10
Therapeutics Development 11
Metastatic Breast Cancer - Therapeutics under Development by Companies 13
Metastatic Breast Cancer - Therapeutics under Investigation by Universities/Institutes 23
Metastatic Breast Cancer - Pipeline Products Glance 24
Metastatic Breast Cancer - Products under Development by Companies 28
Metastatic Breast Cancer - Products under Investigation by Universities/Institutes 45
Metastatic Breast Cancer - Companies Involved in Therapeutics Development 46
Metastatic Breast Cancer - Therapeutics Assessment 185
Drug Profiles 220
Metastatic Breast Cancer - Dormant Projects 1033
Metastatic Breast Cancer - Discontinued Products 1049
Metastatic Breast Cancer - Product Development Milestones 1055
Appendix 1068
List of Tables
Number of Products under Development for Metastatic Breast Cancer, H2 2016 38
Number of Products under Development for Metastatic Breast Cancer - Comparative Analysis, H2 2016 39
Number of Products under Development by Companies, H2 2016 40
Number of Products under Development by Companies, H2 2016 (Contd..1) 41
Number of Products under Development by Companies, H2 2016 (Contd..2) 42
Number of Products under Development by Companies, H2 2016 (Contd..3) 43
Number of Products under Development by Companies, H2 2016 (Contd..4) 44
Number of Products under Development by Companies, H2 2016 (Contd..5) 45
Number of Products under Development by Companies, H2 2016 (Contd..6) 46
Number of Products under Development by Companies, H2 2016 (Contd..7) 47
Number of Products under Development by Companies, H2 2016 (Contd..8) 48
Number of Products under Development by Companies, H2 2016 (Contd..9) 49
Number of Products under Investigation by Universities/Institutes, H2 2016 50
Comparative Analysis by Late Stage Development, H2 2016 51
Comparative Analysis by Clinical Stage Development, H2 2016 52
Comparative Analysis by Early Stage Development, H2 2016 53
Comparative Analysis by Unknown Stage Development, H2 2016 54
Products under Development by Companies, H2 2016 55
Products under Development by Companies, H2 2016 (Contd..1) 56
Products under Development by Companies, H2 2016 (Contd..2) 57
Products under Development by Companies, H2 2016 (Contd..3) 58
Products under Development by Companies, H2 2016 (Contd..4) 59
Products under Development by Companies, H2 2016 (Contd..5) 60
Products under Development by Companies, H2 2016 (Contd..6) 61
Products under Development by Companies, H2 2016 (Contd..7) 62
Products under Development by Companies, H2 2016 (Contd..8) 63
Products under Development by Companies, H2 2016 (Contd..9) 64
Products under Development by Companies, H2 2016 (Contd..10) 65
Products under Development by Companies, H2 2016 (Contd..11) 66
Products under Development by Companies, H2 2016 (Contd..12) 67
Products under Development by Companies, H2 2016 (Contd..13) 68
Products under Development by Companies, H2 2016 (Contd..14) 69
Products under Development by Companies, H2 2016 (Contd..15) 70
Products under Development by Companies, H2 2016 (Contd..16) 71
Products under Investigation by Universities/Institutes, H2 2016 72
Metastatic Breast Cancer - Pipeline by 3SBio Inc, H2 2016 73
Metastatic Breast Cancer - Pipeline by AB Science SA, H2 2016 74
Metastatic Breast Cancer - Pipeline by AbbVie Inc, H2 2016 75
Metastatic Breast Cancer - Pipeline by Acceleron Pharma Inc, H2 2016 76
Metastatic Breast Cancer - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 77
Metastatic Breast Cancer - Pipeline by Adgero Biopharmaceuticals Inc, H2 2016 78
Metastatic Breast Cancer - Pipeline by Advaxis Inc, H2 2016 79
Metastatic Breast Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016 80
Metastatic Breast Cancer - Pipeline by Alteogen Inc, H2 2016 81
Metastatic Breast Cancer - Pipeline by Amarna Therapeutics BV, H2 2016 82
Metastatic Breast Cancer - Pipeline by Ambrx Inc, H2 2016 83
Metastatic Breast Cancer - Pipeline by Amgen Inc, H2 2016 84
Metastatic Breast Cancer - Pipeline by Aphios Corp, H2 2016 85
Metastatic Breast Cancer - Pipeline by Arvinas Inc, H2 2016 86
Metastatic Breast Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2016 87
Metastatic Breast Cancer - Pipeline by Astellas Pharma Inc, H2 2016 88
Metastatic Breast Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016 89
Metastatic Breast Cancer - Pipeline by AstraZeneca Plc, H2 2016 90
Metastatic Breast Cancer - Pipeline by Bayer AG, H2 2016 91
Metastatic Breast Cancer - Pipeline by Beta Pharma Inc, H2 2016 92
Metastatic Breast Cancer - Pipeline by Biocon Ltd, H2 2016 93
Metastatic Breast Cancer - Pipeline by Bionovis SA, H2 2016 94
Metastatic Breast Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 95
Metastatic Breast Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 96
Metastatic Breast Cancer - Pipeline by Cantex Pharmaceuticals Inc, H2 2016 97
Metastatic Breast Cancer - Pipeline by Cascadian Therapeutics Inc, H2 2016 98
Metastatic Breast Cancer - Pipeline by CASI Pharmaceuticals Inc, H2 2016 99
Metastatic Breast Cancer - Pipeline by Celgene Corp, H2 2016 100
Metastatic Breast Cancer - Pipeline by Celldex Therapeutics Inc, H2 2016 101
Metastatic Breast Cancer - Pipeline by Cellectar Biosciences Inc, H2 2016 102
Metastatic Breast Cancer - Pipeline by Celltrion Inc, H2 2016 103
Metastatic Breast Cancer - Pipeline by Clovis Oncology Inc, H2 2016 104
Metastatic Breast Cancer - Pipeline by Corcept Therapeutics Inc, H2 2016 105
Metastatic Breast Cancer - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016 106
Metastatic Breast Cancer - Pipeline by Curadis GmbH, H2 2016 107
Metastatic Breast Cancer - Pipeline by Curaxys SL, H2 2016 108
Metastatic Breast Cancer - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 109
Metastatic Breast Cancer - Pipeline by Deciphera Pharmaceuticals LLC, H2 2016 110
Metastatic Breast Cancer - Pipeline by DexTech Medical AB, H2 2016 111
Metastatic Breast Cancer - Pipeline by Dompe Farmaceutici SpA, H2 2016 112
Metastatic Breast Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016 113
Metastatic Breast Cancer - Pipeline by EirGenix Inc, H2 2016 114
Metastatic Breast Cancer - Pipeline by Eisai Co Ltd, H2 2016 115
Metastatic Breast Cancer - Pipeline by Eli Lilly and Company, H2 2016 116
Metastatic Breast Cancer - Pipeline by Ensol Biosciences Inc, H2 2016 117
Metastatic Breast Cancer - Pipeline by EOS Biosciences Inc, H2 2016 118
Metastatic Breast Cancer - Pipeline by Epigen Biosciences Inc, H2 2016 119
Metastatic Breast Cancer - Pipeline by Etubics Corp, H2 2016 120
Metastatic Breast Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 121
Metastatic Breast Cancer - Pipeline by FibroGen Inc, H2 2016 122
Metastatic Breast Cancer - Pipeline by Gene Techno Science Co Ltd, H2 2016 123
Metastatic Breast Cancer - Pipeline by Genelux Corp, H2 2016 124
Metastatic Breast Cancer - Pipeline by Genentech Inc, H2 2016 125
Metastatic Breast Cancer - Pipeline by Genor BioPharma Co Ltd, H2 2016 126
Metastatic Breast Cancer - Pipeline by Gilead Sciences Inc, H2 2016 127
Metastatic Breast Cancer - Pipeline by Glycotope GmbH, H2 2016 128
Metastatic Breast Cancer - Pipeline by GP Pharm SA, H2 2016 129
Metastatic Breast Cancer - Pipeline by GTx Inc, H2 2016 130
Metastatic Breast Cancer - Pipeline by Halozyme Therapeutics Inc, H2 2016 131
Metastatic Breast Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 132
Metastatic Breast Cancer - Pipeline by Hetero Drugs Ltd, H2 2016 133
Metastatic Breast Cancer - Pipeline by Humorigin Biotechnology Corp, H2 2016 134
Metastatic Breast Cancer - Pipeline by Immune Design Corp, H2 2016 135
Metastatic Breast Cancer - Pipeline by Immunomedics Inc, H2 2016 136
Metastatic Breast Cancer - Pipeline by Immunophotonics Inc, H2 2016 137
Metastatic Breast Cancer - Pipeline by Immupharma Plc, H2 2016 138
Metastatic Breast Cancer - Pipeline by Incyte Corp, H2 2016 139
Metastatic Breast Cancer - Pipeline by Intas Pharmaceuticals Ltd, H2 2016 140
Metastatic Breast Cancer - Pipeline by Ionis Pharmaceuticals Inc, H2 2016 141
Metastatic Breast Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2016 142
Metastatic Breast Cancer - Pipeline by Johnson & Johnson, H2 2016 143
Metastatic Breast Cancer - Pipeline by Kadmon Corp LLC, H2 2016 144
Metastatic Breast Cancer - Pipeline by Kancera AB, H2 2016 145
Metastatic Breast Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2016 146
Metastatic Breast Cancer - Pipeline by Laboratoires Pierre Fabre SA, H2 2016 147
Metastatic Breast Cancer - Pipeline by Mabion SA, H2 2016 148
Metastatic Breast Cancer - Pipeline by MacroGenics Inc, H2 2016 149
Metastatic Breast Cancer - Pipeline by MandalMed Inc, H2 2016 150
Metastatic Breast Cancer - Pipeline by Meabco A/S, H2 2016 151
Metastatic Breast Cancer - Pipeline by MedImmune LLC, H2 2016 152
Metastatic Breast Cancer - Pipeline by Medivation Inc, H2 2016 153
Metastatic Breast Cancer - Pipeline by Merck & Co Inc, H2 2016 154
Metastatic Breast Cancer - Pipeline by Merck KGaA, H2 2016 155
Metastatic Breast Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H2 2016 156
Metastatic Breast Cancer - Pipeline by Merus NV, H2 2016 157
Metastatic Breast Cancer - Pipeline by MetaStat Inc, H2 2016 158
Metastatic Breast Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 159
Metastatic Breast Cancer - Pipeline by Morphotek Inc, H2 2016 160
Metastatic Breast Cancer - Pipeline by Mycenax Biotech Inc, H2 2016 161
Metastatic Breast Cancer - Pipeline by NantKwest Inc, H2 2016 162
Metastatic Breast Cancer - Pipeline by Natco Pharma Ltd, H2 2016 163
Metastatic Breast Cancer - Pipeline by Nektar Therapeutics, H2 2016 164
Metastatic Breast Cancer - Pipeline by Neonc Technologies Inc, H2 2016 165
Metastatic Breast Cancer - Pipeline by NewLink Genetics Corp, H2 2016 166
Metastatic Breast Cancer - Pipeline by Nippon Kayaku Co Ltd, H2 2016 167
Metastatic Breast Cancer - Pipeline by Northwest Biotherapeutics Inc, H2 2016 168
Metastatic Breast Cancer - Pipeline by Novartis AG, H2 2016 169
Metastatic Breast Cancer - Pipeline by Oasmia Pharmaceutical AB, H2 2016 170
Metastatic Breast Cancer - Pipeline by OBI Pharma Inc, H2 2016 171
Metastatic Breast Cancer - Pipeline by Oncobiologics Inc, H2 2016 172
Metastatic Breast Cancer - Pipeline by Oncolytics Biotech Inc, H2 2016 173
Metastatic Breast Cancer - Pipeline by OncoMed Pharmaceuticals Inc, H2 2016 174
Metastatic Breast Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 175
Metastatic Breast Cancer - Pipeline by Panacea Pharmaceuticals Inc, H2 2016 176
Metastatic Breast Cancer - Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2016 177
Metastatic Breast Cancer - Pipeline by Pfizer Inc, H2 2016 178
Metastatic Breast Cancer - Pipeline by Pharma Mar SA, H2 2016 179
Metastatic Breast Cancer - Pipeline by PIQUR Therapeutics AG, H2 2016 180
Metastatic Breast Cancer - Pipeline by Plexxikon Inc, H2 2016 181
Metastatic Breast Cancer - Pipeline by Polaris Pharmaceuticals Inc, H2 2016 182
Metastatic Breast Cancer - Pipeline by Polyphor Ltd, H2 2016 183
Metastatic Breast Cancer - Pipeline by Prescient Therapeutics Ltd, H2 2016 184
Metastatic Breast Cancer - Pipeline by Prima BioMed Ltd, H2 2016 185
Metastatic Breast Cancer - Pipeline by Puma Biotechnology Inc, H2 2016 186
Metastatic Breast Cancer - Pipeline by Radius Health Inc, H2 2016 187
Metastatic Breast Cancer - Pipeline by Richter Gedeon Nyrt, H2 2016 188
Metastatic Breast Cancer - Pipeline by Samyang Holdings Corp, H2 2016 189
Metastatic Breast Cancer - Pipeline by Sanofi, H2 2016 190
Metastatic Breast Cancer - Pipeline by Seattle Genetics Inc, H2 2016 191
Metastatic Breast Cancer - Pipeline by Shanghai Henlius Biotech Co Ltd, H2 2016 192
Metastatic Breast Cancer - Pipeline by Sorrento Therapeutics Inc, H2 2016 193
Metastatic Breast Cancer - Pipeline by Starpharma Holdings Ltd, H2 2016 194
Metastatic Breast Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2016 195
Metastatic Breast Cancer - Pipeline by SynCore Biotechnology Co Ltd, H2 2016 196
Metastatic Breast Cancer - Pipeline by Syndax Pharmaceuticals Inc, H2 2016 197
Metastatic Breast Cancer - Pipeline by Synthon Holdings BV, H2 2016 198
Metastatic Breast Cancer - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2016 199
Metastatic Breast Cancer - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 200
Metastatic Breast Cancer - Pipeline by Tocagen Inc, H2 2016 201
Metastatic Breast Cancer - Pipeline by Transgene Biotek Ltd, H2 2016 202
Metastatic Breast Cancer - Pipeline by Tyme Technologies Inc, H2 2016 203
Metastatic Breast Cancer - Pipeline by Vaxil Bio Therapeutics Ltd, H2 2016 204
Metastatic Breast Cancer - Pipeline by Vertex Pharmaceuticals Inc, H2 2016 205
Metastatic Breast Cancer - Pipeline by VioQuest Pharmaceuticals Inc, H2 2016 206
Metastatic Breast Cancer - Pipeline by Vyriad Inc, H2 2016 207
Metastatic Breast Cancer - Pipeline by Wilex AG, H2 2016 208
Metastatic Breast Cancer - Pipeline by WntResearch AB, H2 2016 209
Metastatic Breast Cancer - Pipeline by ZIOPHARM Oncology Inc, H2 2016 210
Metastatic Breast Cancer - Pipeline by Zymeworks Inc, H2 2016 211
Assessment by Monotherapy Products, H2 2016 212
Assessment by Combination Products, H2 2016 213
Number of Products by Stage and Target, H2 2016 215
Number of Products by Stage and Mechanism of Action, H2 2016 229
Number of Products by Stage and Route of Administration, H2 2016 244
Number of Products by Stage and Molecule Type, H2 2016 246
Metastatic Breast Cancer - Dormant Projects, H2 2016 1060
Metastatic Breast Cancer - Dormant Projects (Contd..1), H2 2016 1061
Metastatic Breast Cancer - Dormant Projects (Contd..2), H2 2016 1062
Metastatic Breast Cancer - Dormant Projects (Contd..3), H2 2016 1063
Metastatic Breast Cancer - Dormant Projects (Contd..4), H2 2016 1064
Metastatic Breast Cancer - Dormant Projects (Contd..5), H2 2016 1065
Metastatic Breast Cancer - Dormant Projects (Contd..6), H2 2016 1066
Metastatic Breast Cancer - Dormant Projects (Contd..7), H2 2016 1067
Metastatic Breast Cancer - Dormant Projects (Contd..8), H2 2016 1068
Metastatic Breast Cancer - Dormant Projects (Contd..9), H2 2016 1069
Metastatic Breast Cancer - Dormant Projects (Contd..10), H2 2016 1070
Metastatic Breast Cancer - Dormant Projects (Contd..11), H2 2016 1071
Metastatic Breast Cancer - Dormant Projects (Contd..12), H2 2016 1072
Metastatic Breast Cancer - Dormant Projects (Contd..13), H2 2016 1073
Metastatic Breast Cancer - Dormant Projects (Contd..14), H2 2016 1074
Metastatic Breast Cancer - Dormant Projects (Contd..15), H2 2016 1075
Metastatic Breast Cancer - Discontinued Products, H2 2016 1076
Metastatic Breast Cancer - Discontinued Products (Contd..1), H2 2016 1077
Metastatic Breast Cancer - Discontinued Products (Contd..2), H2 2016 1078
Metastatic Breast Cancer - Discontinued Products (Contd..3), H2 2016 1079
Metastatic Breast Cancer - Discontinued Products (Contd..4), H2 2016 1080
Metastatic Breast Cancer - Discontinued Products (Contd..5), H2 2016 1081
List of Figures
Number of Products under Development for Metastatic Breast Cancer, H2 2016 38
Number of Products under Development for Metastatic Breast Cancer - Comparative Analysis, H2 2016 39
Number of Products under Development by Companies, H2 2016 40
Number of Products under Investigation by Universities/Institutes, H2 2016 50
Comparative Analysis by Late Stage Development, H2 2016 51
Comparative Analysis by Clinical Stage Development, H2 2016 52
Comparative Analysis by Early Stage Products, H2 2016 53
Assessment by Monotherapy Products, H2 2016 212
Assessment by Combination Products, H2 2016 213
Number of Products by Top 10 Targets, H2 2016 214
Number of Products by Stage and Top 10 Targets, H2 2016 214
Number of Products by Top 10 Mechanism of Actions, H2 2016 228
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 228
Number of Products by Top 10 Routes of Administration, H2 2016 243
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 243
Number of Products by Top 10 Molecule Types, H2 2016 245
Number of Products by Stage and Top 10 Molecule Types, H2 2016 245
